Literature DB >> 34043417

Nonalcoholic Fatty Liver Disease: An Emerging Driver of Cardiac Arrhythmia.

Ze Chen1,2,3, Jiayi Liu1,3, Feng Zhou4,3, Haomiao Li1,4,3, Xiao-Jing Zhang1,3, Zhi-Gang She1,3, Zhibing Lu2, Jingjing Cai5,3, Hongliang Li1,3,6.   

Abstract

Cardiac arrhythmias and the resulting sudden cardiac death are significant cardiovascular complications that continue to impose a heavy burden on patients and society. An emerging body of evidence indicates that nonalcoholic fatty liver disease (NAFLD) is closely associated with the risk of cardiac arrhythmias, independent of other conventional cardiometabolic comorbidities. Although most studies focus on the relationship between NAFLD and atrial fibrillation, associations with ventricular arrhythmias and cardiac conduction defects have also been reported. Mechanistic investigations suggest that a number of NAFLD-related pathophysiological alterations may potentially elicit structural, electrical, and autonomic remodeling in the heart, contributing to arrhythmogenic substrates in the heart. NAFLD is now the most common liver and metabolic disease in the world. However, the upsurge in the prevalence of NAFLD as an emerging risk factor for cardiac arrhythmias has received little attention. In this review, we summarize the clinical evidence and putative pathophysiological mechanisms for the emerging roles of NAFLD in cardiac arrhythmias, with the purpose of highlighting the notion that NAFLD may serve as an independent risk factor and a potential driving force in the development and progression of cardiac arrhythmias.

Entities:  

Keywords:  arrhythmia, cardiac; atrial fibrillation; nonalcoholic fatty liver disease; prevalence; risk factor

Mesh:

Year:  2021        PMID: 34043417     DOI: 10.1161/CIRCRESAHA.121.319059

Source DB:  PubMed          Journal:  Circ Res        ISSN: 0009-7330            Impact factor:   17.367


  10 in total

1.  Increasing Adiposity Is Associated With QTc Interval Prolongation and Increased Ventricular Arrhythmic Risk in the Context of Metabolic Dysfunction: Results From the UK Biobank.

Authors:  Kiran Haresh Kumar Patel; Xinyang Li; Xiao Xu; Lin Sun; Maddalena Ardissino; Prakash P Punjabi; Sanjay Purkayastha; Nicholas S Peters; James S Ware; Fu Siong Ng
Journal:  Front Cardiovasc Med       Date:  2022-06-29

2.  Identification of genes and key pathways underlying the pathophysiological association between nonalcoholic fatty liver disease and atrial fibrillation.

Authors:  Yanan Chu; Fangcong Yu; Yakui Wu; Jinxiu Yang; Jiaran Shi; Tianxin Ye; Deheng Han; Xingxiang Wang
Journal:  BMC Med Genomics       Date:  2022-07-05       Impact factor: 3.622

Review 3.  Non-Alcoholic Fatty Liver Disease and Risk of Macro- and Microvascular Complications in Patients with Type 2 Diabetes.

Authors:  Alessandro Mantovani; Andrea Dalbeni; Giorgia Beatrice; Davide Cappelli; Fernando Gomez-Peralta
Journal:  J Clin Med       Date:  2022-02-12       Impact factor: 4.241

Review 4.  Bidirectional Association between Hypertension and NAFLD: A Systematic Review and Meta-Analysis of Observational Studies.

Authors:  Gerui Li; Yuanyuan Peng; Ze Chen; Hang Li; Danli Liu; Xujun Ye
Journal:  Int J Endocrinol       Date:  2022-03-24       Impact factor: 3.257

5.  Comparative Efficacy of Chinese Patent Medicines for Clearing Heat and Dampness in the Treatment of NAFLD: A Network Meta-Analysis of Real-World Evidence.

Authors:  Yuan Xu; Yan Wang; Xiao-Jun Gou; Man Wang
Journal:  Evid Based Complement Alternat Med       Date:  2022-07-31       Impact factor: 2.650

Review 6.  Management of Dyslipidemia in Patients with Non-Alcoholic Fatty Liver Disease.

Authors:  Hans-Michael Steffen; Philipp Kasper; Anna Martin; Sonja Lang; Tobias Goeser; Münevver Demir
Journal:  Curr Atheroscler Rep       Date:  2022-05-04       Impact factor: 5.967

7.  Switch-associated protein 70 protects against nonalcoholic fatty liver disease through suppression of TAK1.

Authors:  Qiaofeng Qian; Yang Li; Jiajun Fu; Dewen Leng; Zhe Dong; Jiajun Shi; Hongjie Shi; Dengwei Cao; Xu Cheng; Yufeng Hu; Qiujie Luo; Manli Hu; Yong Ran; Hao Tang; Hui Liu; Jinping Liu
Journal:  Hepatology       Date:  2022-04-25       Impact factor: 17.298

8.  High liver fibrosis scores in metabolic dysfunction-associated fatty liver disease patients are associated with adverse atrial remodeling and atrial fibrillation recurrence following catheter ablation.

Authors:  Raphaël Decoin; Laura Butruille; Thomas Defrancq; Jordan Robert; Nicolas Destrait; Augustin Coisne; Samy Aghezzaf; Eloise Woitrain; Zouriatou Gouda; Sofia Schino; Cédric Klein; Patrice Maboudou; François Brigadeau; Didier Klug; Andre Vincentelli; David Dombrowicz; Bart Staels; David Montaigne; Sandro Ninni
Journal:  Front Endocrinol (Lausanne)       Date:  2022-08-31       Impact factor: 6.055

9.  The prevalence of MAFLD and its association with atrial fibrillation in a nationwide health check-up population in China.

Authors:  Fang Lei; Juan-Juan Qin; Xiaohui Song; Ye-Mao Liu; Ming-Ming Chen; Tao Sun; Xuewei Huang; Ke-Qiong Deng; Xiuran Zuo; Dongai Yao; Li-Juan Xu; Huiming Lu; Gang Wang; Feng Liu; Lidong Chen; Jie Luo; Jiahong Xia; Lin Wang; QiongYu Yang; Peng Zhang; Yan-Xiao Ji; Xiao-Jing Zhang; Zhi-Gang She; Qiang Zeng; Hongliang Li; Jingjing Cai
Journal:  Front Endocrinol (Lausanne)       Date:  2022-09-27       Impact factor: 6.055

Review 10.  Mediterranean Diet: A Tool to Break the Relationship of Atrial Fibrillation with the Metabolic Syndrome and Non-Alcoholic Fatty Liver Disease.

Authors:  Flavio Giuseppe Biccirè; Tommaso Bucci; Danilo Menichelli; Vittoria Cammisotto; Pasquale Pignatelli; Roberto Carnevale; Daniele Pastori
Journal:  Nutrients       Date:  2022-03-16       Impact factor: 5.717

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.